Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX-102 · 3 trials · 3 indications
Time to clearance of anterior chamber cells was defined as the time from initiation of study drug to when a cell count of 0 was achieved and maintained (without cell count increases to \>0) to Week 4 and without rescue or discontinuation due to rescue prior to Week 4. Anterior chamber cell count is the number of cells visible within the anterior chamber of the eye, measured using a slit lamp and following SUN (Standardization of Uveitis Nomenclature) where a cell count \<1 is Grade 0 (absent) and a cell count of \>50 is Grade 4+ (severe).
Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
| Arm | Type | Description |
|---|---|---|
| ADX-102 Ophthalmic Solution (0.5%) | EXPERIMENTAL | - |
| Vehicle of ADX-102 Ophthalmic Solution | PLACEBO_COMPARATOR | - |
| ADX-102 Ophthalmic Solution (0.1%) | EXPERIMENTAL | - |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | EXPERIMENTAL | - |
| ADX-102 Ophthalmic Drops (0.5%) | EXPERIMENTAL | ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks. |
| ADX-102 Ophthalmic Drops (0.1%) | EXPERIMENTAL | ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks. |
| Vehicle of ADX-102 Ophthalmic Drops | PLACEBO_COMPARATOR | Vehicle of ADX-102 Ophthalmic Drops |
| Name | Type | Description |
|---|---|---|
| ADX-102 Ophthalmic Solution (0.5%) | DRUG | ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks. |
| Vehicle of ADX-102 Ophthalmic Solution | DRUG | Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks. |
| ADX-102 Ophthalmic Solution (0.1%) | DRUG | ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks. |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | DRUG | ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks. |
| ADX-102 Ophthalmic Drops (0.5%) | DRUG | ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks. |
| ADX-102 Ophthalmic Drops (0.1%) | DRUG | ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks. |
| Vehicle of ADX-102 Ophthalmic Drops | DRUG | Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks. |
Inclusion Criteria: * Male or female subjects aged ≥ 18 years and ≤ 85 years. * Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks. * Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non...
ADX-102 is an investigational small molecule being studied for allergic conjunctivitis, dry eye syndromes, and non-infectious anterior uveitis. It is being developed by Aldeyra Therapeutics, Inc. (ALDX) and has completed clinical trials in these indications.
ADX-102 is being developed by Aldeyra Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker ALDX. The company is conducting clinical research on this investigational small molecule for inflammatory eye conditions.
ADX-102 is an investigational drug that has completed Phase 2 and Phase 3 clinical trials. It is not FDA approved and remains in clinical development. The most advanced trial was a Phase 3 study in non-infectious anterior uveitis.
ADX-102 has completed three clinical trials: NCT03012165, a Phase 2 study in allergic conjunctivitis with 154 participants; NCT03131154, a Phase 3 trial in non-infectious anterior uveitis with 123 participants; and NCT03162783, a Phase 2 study in dry eye syndromes with 51 participants.
No alternative names for ADX-102 have been disclosed in the available clinical trial information. The drug is referred to solely as ADX-102 in the studies registered on ClinicalTrials.gov.